Abstract
Merck on February 13 announced the approval of tafluprost ophthalmic solution for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company expects the product to be available in March under the brand name Zioptan. FDA-approved labeling
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
